Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients
- PMID: 2382846
- DOI: 10.1097/00000542-199008000-00004
Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients
Abstract
The pharmacokinetics of propofol were determined in nine patients (seven men, two women, (mean +/- SD) 55.8 +/- 21.2 yr, 65.2 +/- 8 kg) requiring prolonged mechanical ventilation of their lungs. After an initial dose of 1-3 mg/kg, propofol was administered iv at 3 mg/kg/h for 72 h. Arterial blood samples were collected at selected times during and up to 72 h after infusion. Propofol whole blood concentrations were determined by high-performance liquid chromatography with fluorescence detection. Individual pharmacokinetic parameters were estimated by noncompartmental analysis. Derived pharmacokinetic parameters showed a long terminal phase (T1/2 = 1878 +/- 672 min), a large volume of distribution at steady state (Vdss = 1666 +/- 756 l), and a high total body clearance (Cl = 1.57 +/- 0.56 l/min). While the propofol terminal elimination half-life is longer than that previously reported, emergence from sedation after prolonged administration will be governed by both redistribution mechanisms arising from the large distribution volumes and elimination from the body.
Similar articles
-
Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients.Intensive Care Med. 1995 Dec;21(12):981-8. doi: 10.1007/BF01700659. Intensive Care Med. 1995. PMID: 8750122 Clinical Trial.
-
Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients.Br J Anaesth. 1992 May;68(5):486-91. doi: 10.1093/bja/68.5.486. Br J Anaesth. 1992. PMID: 1642937
-
Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.Clin Pharmacol Ther. 2002 Dec;72(6):670-84. doi: 10.1067/mcp.2002.129500. Clin Pharmacol Ther. 2002. PMID: 12496748 Clinical Trial.
-
Pharmacokinetic implications for the clinical use of propofol.Clin Pharmacokinet. 1989 Nov;17(5):308-26. doi: 10.2165/00003088-198917050-00002. Clin Pharmacokinet. 1989. PMID: 2684471 Review.
-
Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit.Crit Care Clin. 1995 Oct;11(4):827-47. Crit Care Clin. 1995. PMID: 8535981 Review.
Cited by
-
Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery.J Pharmacokinet Pharmacodyn. 2015 Apr;42(2):111-22. doi: 10.1007/s10928-015-9404-6. Epub 2015 Jan 28. J Pharmacokinet Pharmacodyn. 2015. PMID: 25628234 Free PMC article.
-
Total body propofol clearance (TBPC) after living-donor liver transplantation (LDLT) surgery is decreased in patients with a long warm ischemic time.J Anesth. 2006;20(4):323-6. doi: 10.1007/s00540-006-0420-y. J Anesth. 2006. PMID: 17072701
-
Propofol: a review of its use in intensive care sedation of adults.CNS Drugs. 2003;17(4):235-72. doi: 10.2165/00023210-200317040-00003. CNS Drugs. 2003. PMID: 12665397 Review.
-
Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.Drugs. 2012 Oct 1;72(14):1881-916. doi: 10.2165/11636220-000000000-00000. Drugs. 2012. PMID: 22950534 Review.
-
Propofol emulsion reduces proliferative responses of lymphocytes from intensive care patients.Intensive Care Med. 1993;19(5):299-302. doi: 10.1007/BF01690552. Intensive Care Med. 1993. PMID: 8408941 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources